In the U.S., approval of generic congeners of branded drugs requires bioequivalence. (1) Bioequivalence is determined by serum concentration parameters (e.g., area under the curve, peak concentrations) within a defined range of those obtained with the parent proprietary compound. No clinical testing of outcomes, tolerance, etc. are necessary.
Credits: James A. Reiffel